Japan’s Astellas acquires immuno-oncology therapeutics firm Xyphos
Xyphos’ synthetic biology platform directs cells of the immune system to target single or multiple tumor antigens. Credit: Pixabay/Colin Behrens.
NS Medical Devices is using cookies
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X